Antagonism of human formyl peptide receptor for treatment of disease

A methyl and alkyl technology, applied in the field of antagonism of human formyl peptide receptors for the treatment of diseases, can solve problems such as toxicity hindering long-term use, side effects hindering widespread or universal use, etc.

Inactive Publication Date: 2012-11-28
NIKAN PHARMA
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Short-term high-dose ibuprofen or other anti-inflammatory agents can be useful in addressing the deep and protracted inflammation characteristic of CF lungs, but toxicity to the liver and other organs, especially in pediatric patients, prevents their long-term use
Similarly, corticosteroid therapies have some utility, but side effects prevent their widespread or common use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antagonism of human formyl peptide receptor for treatment of disease
  • Antagonism of human formyl peptide receptor for treatment of disease
  • Antagonism of human formyl peptide receptor for treatment of disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0044] Cyclosporin H (CsH) is known to be a specific antagonist of formyl peptide receptors (Wenzel-Seifert et al., 1991; Wenzel-Seifert and Seifert, 1993). Provided herein are therapeutic uses of FPR antagonists for the treatment of eosinophil-associated and neutrophil-associated diseases and disorders, including those listed above. In preferred embodiments, such antagonists include CsH and derivatives thereof that act as potent and specific FPR antagonists (eg, dihydroCsH and compounds of formula I). The cyclosporins of the present invention are administered at doses that produce a reduction in circulating eosinophils or neutrophils or a reduction in eosinophils or neutrophils in contrast to eosinophils or neutrophils. A decrease in disease-associated sites of increased granulocyte function or local cell numbers, or a decrease in the activation of eosinophils or neutrophils at such sites.

[0045] Compounds of the invention

[0046] In one aspect, the present invention p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is directed to modulators of eosinophilic and neutrophilic function and the use of such modulators for treatment of eosinophil-associated and neutrophil-associated diseases.

Description

Background technique [0001] Eosinophils and neutrophils are blood cells that play an important role in the immune response. Eosinophils are immune cells that, in addition to their role in fighting parasitic infections, have been implicated in a variety of immune and allergic diseases. They form in the bone marrow and migrate into the blood. Unstimulated circulating eosinophils remain in the bloodstream for 8-12 hours. There are a variety of factors that regulate eosinophil differentiation, including IL-3, IL-5, and GM-CSF. In particular, animal models were the first to show that IL-5 plays a dominant role in the diffusion and migration of eosinophils from the bone marrow to the bloodstream and to the lungs. [0002] Asthma is a highly prevalent allergic disease with complex and poorly understood etiology. Although a variety of animal (eg, mouse) models exist, no single animal model accurately captures all of the physiological and pathological features of the disease. None...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D259/00C07D405/02A61K31/549A61P37/02
CPCC07D405/06A61K31/549C07D405/04C07D259/00A61P1/00A61P1/04A61P7/00A61P9/10A61P11/00A61P11/06A61P17/00A61P17/06A61P17/10A61P29/00A61P37/00A61P37/02A61P37/08A61K38/12C07K7/64
Inventor J·D·本森
Owner NIKAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products